Demonstrating Denifanstat’s Differentiated Approach in MASH with Mechanistic & Clinical Data Showing Direct Anti-Fibrotic Activity
Time: 4:15 pm
day: Conf Day 2 PM
Details:
- Use of primary stellate cells to show that denifanstat directly blocks fibrotic activity
- Demonstrating significant histological efficacy in FASCINATE-2 on endpoints of NASH resolution and fibrosis improvement
- Clinical use of biopsies and biomarkers to manifest effects of FASN inhibition against the 3 hallmarks of MASH; liver fat, inflammation, and fibrosis
